ReviewInternational journal of nanomedicine2021
Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.
Review in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.Discover nano · 2026Review
- Phytochemical Diversity and Antioxidant Potential ofAntioxidants (Basel, Switzerland) · 2026Review
- Therapeutic strategies for ischemic heart disease with natural product-based nanomedicines.Journal of nanobiotechnology · 2026Review
- Cardioprotective effects of naringin, hesperidin, and hesperetin: modulation of atherosclerosis, cardiac remodeling, and myocardial ischemia/infarction.Frontiers in nutrition · 2026Review
- Application Prospects of Nanotechnology in the Diagnosis and Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2026Review
- Nanodelivery of Bioactive Natural Products: A Targeted Therapeutic Breakthrough for Atherosclerosis.Pharmaceutics · 2025Review
- Essential information about nanotechnology in cardiology.Annals of medicine and surgery (2012) · 2025Review
- Use of Herbal Drugs in Cardiovascular Disease- A Review.Current cardiology reviews · 2025Review
- Quercetin Nano-formulations as a Potential Approach for Skin Cancer.Pharmaceutical nanotechnology · 2025Review
- The Potential of Natural Products in Metabolic Disease Management: A Thorough Exploration of the Case of Uganda.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Protective Effects of Anethole inAntioxidants (Basel, Switzerland) · 2024Article
- Review
- The Potential of Natural Products in the Management of Cardiovascular Disease.Current pharmaceutical design · 2024Review
- Nanocurcumin in myocardial infarction therapy: emerging trends and future directions.Frontiers in bioengineering and biotechnology · 2024Review
- Review
- Current Understanding of Polyphenols to Enhance Bioavailability for Better Therapies.Biomedicines · 2023Review
- Cardioprotective effect ofFrontiers in pharmacology · 2023Article
- Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management-Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine.Frontiers in pharmacology · 2023Review
- Article
- Anti-atherosclerotic Effects of Myrtenal in High-Fat Diet-Induced Atherosclerosis in Rats.Applied biochemistry and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the high prevalence of cardiovascular diseases (CVDs), the primary cause of death during the last several decades, it is necessary to develop proper strategies for the prevention and treatment of CVDs. Given the excessive side effects of current therapies, alternative therapeutic approaches like medicinal plants and natural products are preferred. Lower toxicity, chemical diversity, cost-effectiveness, and proven therapeutic potentials make natural products superior compared to other products. Nanoformulation methods improve the solubility, bioavailability, circulation time, surface area-to-volume ratio, systemic adverse side effects, and drug delivery efficiency of these medications. This study intended to review the functionality of the most recent nanoformulated medicinal plants and/or natural products against various cardiovascular conditions such as hypertension, atherosclerosis, thrombosis, and myocardial infarction. Literature review revealed that curcumin, quercetin, and resveratrol were the most applied natural products, respectively. Combination therapy, conjugation, or fabrication of nanoparticles and nanocarriers improved the applications and therapeutic efficacy of herbal- or natural-based nanoformulations. In the context of CVDs prevention and/or treatment, available data suggest that natural-based nanoformulations are considerably efficient, alone or in blend with other herbal/synthetic medicines. However, clinical trials are mandatory to elucidate the safety, cardioprotective effect, and mechanism of actions of nanophytomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.